Hearing loss in Mexican children treated with cisplatin
✍ Scribed by Castelán-Martínez, Osvaldo D.; Jiménez-Méndez, Ricardo; Rodríguez-Islas, Felipe; Fierro-Evans, María; Vázquez-Gómez, Benjamín E.; Medina-Sansón, Aurora; Clark, Patricia; Carleton, Bruce; Ross, Colin; Hildebrand, Claudette; Castañeda-Hernández, Gilberto; Rivas-Ruiz, Rodolfo
- Book ID
- 125832858
- Publisher
- Elsevier Science
- Year
- 2014
- Tongue
- English
- Weight
- 323 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0165-5876
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
21.4% of children developed hearing loss, a percentage similar to previous population studies. • Since all received treatment, we cannot determine directly bisphosphonate effects on hearing loss over time. • However, it appears that bisphosphonates neither increase hearing loss nor stop progression
Carboplatin is less ototoxic than cisplatin, but ototoxicity may occur with carboplatin at higher doses. We evaluated hearing in children with brain tumors treated with conventional dose cisplatin followed by highdose carboplatin. Children under 6 years of age, newly diagnosed with brain tumors, wer